Selected-GenAtlas references SOURCE GeneCards NCBI Gene Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol PVT1 contributors: mct/npt/pgu - updated : 31-08-2015
HGNC name Pvt1 oncogene homolog (mouse)
HGNC id 9709
Corresponding disease
PVT1 Burkitt lymphoma variant/acute lymphoblastic leukemia
Location 8q24.21      Physical location : 128.806.778 - 129.113.498
Synonym name
  • Pvt1 oncogene homolog, MYC activator (mouse)
  • plasmacytoma variant translocation gene 1
  • non-protein coding RNA 79
  • Synonym symbol(s) MGC21751, NCRNA00079
    DNA
    TYPE small rna
    SPECIAL FEATURE arranged in tandem
    STRUCTURE 306.72 kb     9 Exon(s)
    regulatory sequence Promoter
    Binding site
    text structure two putative binding sites for Myc proteins
    MAPPING cloned Y linked N status provisional
    RNA
    TRANSCRIPTS type untranslated
    EXPRESSION
    Type
       expressed in (based on citations)
    organ(s)
    cell lineage
    cell lines highly, in cancer cell lines, restricted in normal cells
    fluid/secretion
    at STAGE
    PROTEIN
    PHYSICAL PROPERTIES
    STRUCTURE
    HOMOLOGY
    interspecies homolog to plasmocytoma variant translocation (pvt-1) murine oncogene
    Homologene
    FAMILY
    CATEGORY protooncogene
    SUBCELLULAR LOCALIZATION
    basic FUNCTION
  • preferential integration site of MuLV in mouse
  • c-myc activator (260kb, 3')
  • playing a role in mediating susceptibility to end-stage renal disease attributable to diabetes
  • essential for the maintenance of cell size of cardiomyocytes and might play a role in the regulation of cardiac hypertrophy
  • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein
  • downstream target of Myc proteins
  • cell & other
    REGULATION
    ASSOCIATED DISORDERS
    corresponding disease(s) PVT1
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral   amplification    
    in breast and ovarian cancer associated with reduced survival duration in patients treated with agents that act through apoptotic mechanisms
    tumoral fusion      
    PVT1-MYC fusion in Group 3 medulloblastoma
    tumoral     --over  
    in gastric carcinoma promotes the development of multidrug resistance (MDR), suggesting an efficacious target for reversing MDR in gastric cancer therapy
    Susceptibility
  • to end-stage renal disease (ESRD) in type 1 diabetes
  • to Hodgkin lymphoma
  • Variant & Polymorphism SNP , other
  • a common haplotype containing the C allele at rs10808565 and the A allele at rs13447075 that was associated with ESRD
  • association between SNP rs2720709 and ESRD (Hanson 2007)
  • SNP increasing the risk of Hodgkin lymphoma
  • Candidate gene
    Marker
    Therapy target
    ANIMAL & CELL MODELS